How Does Cardiovascular Disease First Present in Women and Men? Incidence of 12 Cardiovascular Diseases in a Contemporary Cohort of 1 937 360 People by George, J et al.
1320
A central principle in cardiovascular disease (CVD) man-agement is that the first lifetime diagnosis signals the fail-
ure of primary prevention and the need to initiate secondary 
prevention of recurrent or related CVD events. The decades-
long emphasis given to prevention of myocardial infarction 
(MI) and stroke is reflected in remarkable declines – ≈33% 
over the past decade – in their incidence in developed coun-
tries.1 Incidence rates for chronic CVD presentations such as 
angina or heart failure, although less studied, do not appear 
to have similarly declined.1–3 Consequently, the spectrum of 
initial presentations of CVD in contemporary practice is likely 
to have changed in comparison with the latter part of the last 
century. Cohort studies that report only fatal end points (final 
presentations),4 may have less relevance to informing the suc-
cess of primary prevention than those which investigate initial 
presentations. Within studies that incorporate nonfatal events, 
acute MI and stroke have been more commonly investigated 
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than other chronic presentations.5–7 Large-scale contemporary 
studies that evaluate the first lifetime diagnosis in women and 
men across a wide range of acute and chronic CVDs including 
both fatal and nonfatal presentations can provide additional 
insight into the understanding of CVDs.
Fundamental unanswered questions about initial CVD 
presentation arise. First, what is the relative frequency of dif-
ferent CVDs as they affect women and men in contemporary 
practice? Second, is male sex an equally strong risk factor 
common to all CVDs, or does the association differ across a 
range of diseases?
The lack of large, contemporary, population-based cohorts 
with detailed clinical follow-up spanning hospital and ambula-
tory care has hindered the study of the initial presentation of a 
wide range of acute and chronic CVDs. It has been suggested 
that electronic health record (EHR) data might be meaning-
fully reused8 to create mega-cohorts for such research.9 We 
studied a contemporary, population-based cohort based on 
linked EHRs across primary, secondary, disease registry, and 
death records10–13 to address these 2 questions. We investigated 
a wide range of acquired symptomatic CVDs that are recog-
nized to have differing pathogenic mechanisms.
Methods
Data Sources
Anonymized patients were selected from the Cardiovascular Research 
Using LInked Bespoke Studies and Electronic Records (CALIBER) 
program, described14 and validated10–13,15 elsewhere. Patients were 
linked across 4 clinical data sources: the Clinical Practice Research 
Database (CPRD), the Myocardial Ischemia National Audit Project 
registry, Hospital Episodes Statistics, and the national death registry 
from the Office for National Statistics. CPRD provides primary care 
data on anthropometric measurements, laboratory tests, medical his-
tory, clinical diagnoses, prescriptions, medical procedures, and health 
behaviors, coded using the Read clinical coding scheme. Patients reg-
istered in practices submitting linkable data to CPRD, covering ≈4% 
of the English population, have been found to be representative of the 
English population in terms of age, sex, and ethnicity.16,17 Myocardial 
Ischemia National Audit Project is a national registry of patients 
admitted to the hospital with acute coronary syndromes. Hospital 
Episodes Statistics provides information on diagnoses and medical 
procedures related to all elective and emergency hospital admissions 
across all National Health Service hospitals in England.
Study Population
We studied 1 937 360 patients from 225 general practices across 
England registered between January 1997 and March 2010. We 
required that at study entry patients were aged ≥30 years, were free 
of diagnosed CVD, and had been followed up for at least 1 year. We 
used the entire medical history available on each patient to confirm 
they were free of diagnosed CVD. The look-back period ranged from 
20 years to the minimum of 1 year, which previous research has indi-
cated is a sufficient period to ensure accurate assessment of initial 
disease presentations.18 We used an open cohort design, so patients 
effectively entered the study when they met the inclusion criteria. 
Patients were censored on the earliest date from among: the date of 
first CVD presentation, date of death from other causes, date leaving 
the practice, or date of last practice data collection. (See Figure I in 
the online-only Data Supplement for study flow diagram.)
Risk Factors
The exposures of interest were sex and baseline age, analyzed as 10-year 
age groups between 30 and 80. A priori confounders were baseline age 
as a continuous variable (in analyses estimating associations with sex), 
smoking status, body mass index, systolic blood pressure, total and 
high-density lipoprotein cholesterol, diabetes mellitus, socioeconomic 
status (based on area deprivation measure), use of statins, use of blood 
pressure medication, and, in women only, use of oral contraceptives 
or hormone replacement therapy. The baseline value for these con-
founders was taken as the most recent measurement as recorded during 
consultations in primary care (CPRD) up to 1 year before study entry. 
(Detailed definitions are in online-only Data Supplement Methods I.)
End Points
Primary end points were defined as the first recorded diagnosis of the 
12 most common symptomatic manifestations of CVD, irrespective 
of underlying disease mechanism, arising from pathology in the head, 
heart, abdomen, or legs. The first diagnosis could occur in primary 
care, secondary care, or at death. We studied the following CVDs: 
stable angina, unstable angina, nonfatal MI, unheralded coronary 
death (UCD), heart failure, a composite of cardiac arrest, ventricu-
lar arrhythmia, and sudden cardiac death (SCD), transient ischemic 
attack, ischemic stroke, subarachnoid hemorrhage (SAH), intracere-
bral hemorrhage, abdominal aortic aneurysm (AAA), peripheral arte-
rial disease (PAD), composite CVD, and other deaths. In secondary 
analysis, we examined associations in a subset of nonfatal MIs that 
were classified into ST-segment–elevation MI and non–ST-segment–
elevation MI. Coronary heart disease (CHD) and stroke that were 
not otherwise specified (NOS) were also studied. We classified as 
fatal events where a death record exists for the same calendar date. 
(Overview of codes and data sources used to define cardiovascular 
end points available in online-only Data Supplement Methods II.)
Statistical Analysis
Hazard ratios (HRs) were estimated for the disease-specific Cox pro-
portional-hazards models with length of follow-up as the timescale, 
stratified by practice, with women as the reference category, and 
included interactions between age (linear and quadratic term) and 
sex. Where we estimated the HR for baseline age, we additionally 
stratified by sex, to allow the baseline hazard to vary. The propor-
tional hazard assumption was tested using Schoenfield residuals, with 
no significant effects found.
In the main analyses, we estimated the association of each end 
point with age groups, the age-adjusted association with sex across 
all subjects, and by age group in a model with sex interactions. 
Assuming mutual independence between initial presentations, we 
assessed heterogeneity in the reported associations based on τ2, an 
estimate of the between-group variance of the log hazard ratio, and a 
way of summarizing the variability in effect sizes across all the end 
points in a single statistic.19
In secondary analysis, we examined whether associations with sex 
change after adjusting for smoking status, body mass index, diabetes 
mellitus, systolic blood pressure, total cholesterol, high-density lipo-
protein cholesterol, and social deprivation, or additionally for baseline 
use of blood pressure–lowering medications (diazides, β-blockers, 
angiotensin-converting enzyme inhibitors, angiotensin receptor block-
ers, or calcium channel blockers), statins, oral contraceptives and 
hormone replacement therapy. Missing covariate data were handled 
by multiple imputation. (Methods used for multiple imputation are 
described in online-only Data Supplement Methods III). In sensitivity 
analyses we studied associations between sex and CVDs (1) ignoring 
primary care diagnoses and (2) restricting end points to fatal events.
In a post hoc analysis, we assessed the discrimination of age- and 
sex-adjusted models for each of the 12 end points by calculating the 
separate concordance index (C-index) for each.20
Approval was granted by the Independent Scientific Advisory 
Committee of the Medicines and Healthcare Products Regulatory 
Agency and the Myocardial Ischemia National Audit Project 
Academic Group. We registered the protocol at clinicaltrials.gov 
(NCT01164371).
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Results
Baseline characteristics of the cohort are shown in the Table. 
The cohort was young at baseline, as would be expected from 
a population free from CVD, and 90% were white. Both sys-
tolic and diastolic blood pressure increased with age, as did the 
proportion on blood pressure–lowering medication, with more 
women than men treated at all ages. More men than women 
were current or ex-smokers, the proportion of current smokers 
declining at >60 years of age. Rates of statin prescription were 
low, but were higher in men than in women at all ages.
Initial CVD Presentations
Over a 6-year median follow-up (interquartile range, 2–10), 
114 859 initial CVD presentations were observed (52.3% 
in men), among which nonfatal MI, UCD, and ischemic or 
NOS stroke together accounted for 32.5%. The proportion of 
events varied by sex and age group (Figure 1; Table I in the 
online-only Data Supplement). The most frequent initial CVD 
presentation for men was nonfatal MI, which accounted for 
27.9% of events in the 30 to 39 age group and more than dou-
ble the proportion in women in the same age group (11.2%). 
This proportion declined in men as age increased, becoming 
similar to that in women in the >80 age group. In contrast, 
stable angina and unstable angina accounted for similar pro-
portions of initial presentations in both men and women and 
declined with age. Although evident in younger age groups, 
heart failure and ischemic stroke as an initial presentation 
started to increase in both sexes at age 60 to form the 2 most 
common initial presentations at age >80.
Associations With Age
The strength and shape of the association of CVDs with age 
varied from predominantly linear (in angina and nonfatal MI) 
to strongly quadratic (UCD, stroke, AAA), and from weak 
(SAH, unstable angina, and cardiac arrest/SCD) to very strong 
(heart failure and AAA. (See Figure II in the online-only Data 
Supplement.)
Associations With Sex
SAH was less common in men (HR men versus women, 
0.69; 95% confidence interval [CI], 0.59–0.79); other CVDs 
were positively associated with male sex but with consid-
erable heterogeneity (τ2=0.196; Figure 2). Specifically, the 
age-adjusted HR (all P<0.001) was <1.5 for transient isch-
emic attack, intracerebral hemorrhage, and unstable angina, 
1.5 to 2.0 for stable angina, ischemic stroke, PAD, heart 
failure, and cardiac arrest/SCD, and 3.6 to 5.0 for AAA, MI, 
and UCD. The age-adjusted HR for men versus women was 
4.14 (95% CI, 3.72–4.60) in ST-segment–elevation MI and 
3.18 (95% CI, 2.86–3.52) in non–ST-segment–elevation MI. 
These associations changed little after adjustment for con-
ventional CVD risk factors and baseline medications, with 
the exception of intracerebral hemorrhage, where the asso-
ciation reduced to null (Figure III in the online-only Data 
Supplement).
Table.  Baseline Characteristics in Men and Women by 10-Year Age Groups
30 to 39 40 to 49 50 to 59 60 to 69 70 to 79 >80
Men Women Men Women Men Women Men Women Men Women Men Women
No. of patients 418 755 385 486 211 109 194 172 158 327 159 919 97 300 110 478 52 383 77 894 20 455 51 082
Age, y 33.3 (3.2) 33.3 (3.2) 44.5 (2.9) 44.6 (2.9) 54.4 (2.9) 54.5 (2.9) 64.4 (2.9) 64.5 (2.9) 74.2 (2.8) 74.5 (2.9) 85.2 (4.3) 86.2 (4.8)
White 85.7 86.6 89.1 89.2 94.2 93.5 95.1 94.7 96.0 96.6 97.4 98.1
Most deprived 
quintile
22.8 21.9 19.7 18.6 17.5 16.6 17.4 17.6 18.9 19.4 18.9 18.7
Number of GP visits 
in previous year
3.6 (4.9) 7.1 (6.8) 4.1 (5.5) 6.2 (6.7) 4.4 (6.0) 6.4 (6.8) 5.6 (6.9) 6.9 (7.3) 6.5 (7.7) 7.2 (7.9) 8.1 (9.3) 8.6 (9.3)
Body mass index, 
kg/m2
26.2 (4.5) 25.5 (5.7) 27.1 (4.6) 26.4 (5.9) 27.5 (4.6) 27.1 (5.7) 27.2 (4.3) 27.3 (5.5) 26.3 (4.1) 26.5 (5.2) 24.9 (3.8) 24.4 (4.6)
Systolic BP, mm Hg 126 (14) 117 (13) 130 (15) 124 (16) 136 (17) 133 (18) 141 (18) 141 (18) 145 (19) 148 (20) 144 (21) 147 (22)
Diastolic BP, mm Hg 78 (10) 74 (9) 81 (10) 77 (10) 83 (10) 81 (10) 82 (10) 82 (9) 81 (10) 81 (10) 78 (11) 79 (11)
Total cholesterol, 
mmol/L
5.3 (1.1) 4.9 (1.0) 5.5 (1.1) 5.3 (1.0) 5.4 (1.1) 5.7 (1.1) 5.2 (1.1) 5.7 (1.2) 4.9 (1.1) 5.6 (1.2) 4.6 (1.1) 5.3 (1.2)
HDL, mmol/L 1.2 (0.3) 1.5 (0.4) 1.2 (0.4) 1.5 (0.4) 1.3 (0.4) 1.6 (0.5) 1.3 (0.4) 1.6 (0.4) 1.3 (0.4) 1.6 (0.5) 1.3 (0.4) 1.6 (0.4)
Ex-smoker 13.2 14.5 15.2 12.7 21.2 14.8 27.8 16.3 32.1 17.6 34.7 16.3
Current smoker 27.5 21.3 25.5 19.4 22.1 17.3 16.5 12.5 10.6 7.9 7.6 4.2
Diabetes mellitus 0.9 0.8 2.1 1.4 3.9 2.6 6.9 4.9 8.5 6.3 8.0 6.2
Statins 0.4 0.2 2.1 1.0 5.0 3.5 9.0 7.9 9.2 8.3 7.2 6.3
BP-lowering 
medications
4.2 7.6 8.8 14.1 17.9 25.8 29.8 35.4 38.5 43.7 39.0 45.6
Oral contraceptives . . . 35.0 . . . 10.4 . . . 1.2 . . . 0.1 . . . . . . . . . . . .
HRT . . . 0.7 . . . 9.1 . . . 30.0 . . . 15.1 . . . 3.3 . . . 0.5
*Mean (standard deviation) for continuous variables and % for categorical variables. Continuous variables are the most recently recorded value in the year before 
study entry. BP indicates blood pressure; GP, general practice; HDL, high-density lipoprotein cholesterol; and HRT, hormone replacement therapy.
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Associations between sex and initial CVD presentation were 
differentially modified by age (Figure 3). The largest differences 
in HRs for men versus women were observed in the younger 
(coronary end points) and middle (ischemic stroke, PAD, AAA) 
age groups. Most dramatically, men <60 years old had an >4-
fold higher risk of MI or UCD than similarly aged women. In all 
cases, associations with male sex diminished with age.
Sensitivity Analyses
The pattern and magnitude of associations with sex were simi-
lar in multiply-adjusted analyses to analyses adjusted for age 
alone (see Figure III in the online-only Data Supplement). 
Stable angina and PAD were the only initial presentations 
where the association with male sex differed when the EHRs 
used were restricted to secondary care and mortality (Figure 
IV in the online-only Data Supplement).
Discrimination of Age- and Sex-Adjusted Models 
for Different CVDs
Using disease-specific age and sex coefficients in risk pre-
diction models resulted in markedly different discrimi-
nation performance (Figure V in the online-only Data 
Supplement), with C-indices ranging from very low for 
SAH (0.57; 95% CI, 0.55–0.59) to relatively high for AAA 
(0.86; 95% CI, 0.85–0.88) in comparison with a conven-
tional composite CVD model with C-index of 0.73 (95% 
CI, 0.72–0.73).
Discussion
Objectives Addressed, Summary of Main Findings
By linking EHRs from multiple sources we curated a cohort 
of nearly 2 million patients with >100 000 nonfatal and fatal 
CVD end points of 12 different types. We found that the 
majority of CVD first presentations are not MI or ischemic 
stroke but rather heart failure, angina, transient ischemic 
attack, and PAD. In our contemporary population-based 
cohort, we find that 51.3% of men and 41.2% of women 
experienced some form of CVD during their lifetime, with 
heart failure and stroke (primarily ischemic and NOS) 
becoming more common as the initial presentations in both 
men and women in later life. The variable associations of sex 
and age with different CVDs have important consequences 
for risk prediction.
Importance of Studying First Manifestations  
of CVD
We compared the relative frequency of 12 of the most com-
mon CVDs affecting atherothrombotic processes in the coro-
nary, cerebral, and peripheral circulations, aneurysms in the 
cerebral and peripheral circulations, and disorder of myocar-
dial function and cardiac arrhythmia. This family of diseases 
is clinically relevant, because having one is strongly associ-
ated with the subsequent development of another and should 
initiate a range of secondary preventive interventions.21 
Figure 1. Age and sex distribution of 60 155 events in men and 54 704 in women representing the initial presentation of a wide range of 
CVDs. CHD indicates coronary heart disease; CVD, cardiovascular disease; NOS, not otherwise specified; and SCD, sudden cardiac 
death.
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Despite the insights to be gained from considering the first 
presentation among these diseases together, this first-life-
time-presentation approach has rarely been reported in the 
literature22 and has tended to exclude major diseases such as 
heart failure, been restricted to small cohorts, or reported in 
men only.23–27
Innovative Role of Large-Scale Health Record 
Linkages
Through the use of linked EHRs, we were able to capture 
diseases first presenting in primary care and were not con-
fined to hospitalized cases. Our cohort is population based, 
with >99% of the English population estimated to be reg-
istered with a family physician,28 unlike other recent large 
cohort studies, such as UK Biobank, with response rates 
<10%.29 The size of cohort— nearly 2 million people— pos-
sible with this EHR platform allows us to include serious 
but less commonly diagnosed events such as AAA and SAH, 
and to have sufficient events in women to study sex differ-
ences reliably. We were able to follow up actual events in a 
clinically meaningful 5-year time frame, similar to the time 
horizon of randomized, controlled trials. More broadly, we 
demonstrate the potential of linked EHR cohorts to comple-
ment bespoke, investigator-led cohorts. The UK Biobank,30 
the Research Program for Genes Environment and Health 
in Kaiser,31 and precision medicine initiatives32 all place 
a major emphasis on specific disease types and follow-up 
through health records. Such large EHR cohorts further 
hold out the promise of lower cost to research funders for 
data collection, the intrinsic clinical relevance of real-world 
data, the opportunities to study diseases with higher speci-
ficity given the cohort sizes possible, and the prospect for 
researchers and clinicians to work across the boundaries 
that currently impede the translation of new discoveries into 
public health benefit.33
We expect the pattern of the age and sex associations we 
found with the CVD outcomes to apply to the broader UK 
population and other European populations free from symp-
tomatic CVD. Our patients were drawn from >200 practices 
representative of the English population. Indeed, a recent arti-
cle investigating similar questions in a smaller investigator-led 
Dutch cohort found broadly similar associations, albeit with 
fewer end points.22 Different cohorts, especially those with 
more people from differing ethnic groups or differing baseline 
risk profiles, may well present different associations.
Validity of Risk Factor and Disease Measurements 
in EHRs
Although a principal strength of this study is the ability to 
resolve a wide range of CVDs in a large-scale cohort, the prin-
cipal limitation is the possibility of errors in the individual 
EHR data sources.34,35 However, evidence for the validity of our 
risk factor and disease end points comes from several sources. 
First, in this population, using identical phenotypic definitions 
for these same 12 diseases, we have replicated anticipated risk 
factor – disease associations with systolic and diastolic blood 
pressure,11 type 2 diabetes mellitus,15 smoking,10 and socio-
economic deprivation.12 These findings support the prospec-
tive prognostic validity of both the risk factor and the disease 
measurements. Second, a recent systematic review of studies 
validating diagnoses in CPRD found a median positive predic-
tive value of 88% across a wide range of diagnoses,7 whereas 
a separate systematic review found the accuracy of discharge 
coding in Hospital Episodes Statistics to be 83%.35 Third, the 
associations we found when considering events from all data 
sources (Figure V in the online-only Data Supplement) were 
consistent with those when excluding nonfatal cases or those 
from primary care. The doctors and coders responsible, and 
the information on which these diagnoses are based, differ for 
each data source (primary care, hospital, and death); it was 
reassuring that the associations were broadly similar. Finally, 
we13 and others36 have demonstrated the validity of using 
linked data for end point follow-up.
Male Sex as a Risk Factor for Different CVDs
We demonstrate that male sex does not have a common under-
lying association on the incidence of different CVDs. Rather, 
the strength of this association is highly variable, ranging from 
protective for SAH; minor for transient ischemic attack, intra-
cerebral hemorrhage, and unstable angina; moderate for stable 
angina, ischemic stroke, PAD, heart failure, and cardiac arrest/
SCD; and strong for AAA, MI, and UCD. Additionally, we found 
that these associations change with age, with sex differences 
in proportion of initial presentation of MI and coronary death 
reducing with age, and with heart failure and stroke (ischemic 
and NOS) emerging as the most common initial presentations in 
both sexes. These findings suggest that stratifying patients into 
low-=, intermediate-, and high-risk groups based on their total 
and disease-specific risks,37 accompanied by the establishment 
of new cost-effective treatment thresholds,38 could improve risk 
management, particularly for diseases such as heart failure and 
The vertical grey dotted line corresponds to the HR of the composite CVD endpoint. 
CHD NOS and Stroke NOS excluded from the main display because non-specific 
endpoints; their corresponding estimates are HR 2.03 (95% CI, 1.92-2.15; n=10,895) 
and 1.37 (95% CI, 1.26-1.49; n=9,532). 
Figure 2. Hazard ratios of men in comparison with women for 
initial presentation of 12 different cardiovascular diseases among 
a population of 1.93 million adults. CHD indicates coronary heart 
disease; CI, confidence interval; CVD, cardiovascular disease; 
HR, hazard ratio; NOS, not otherwise specified; and SCD, 
sudden cardiac death.
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stroke that affect high proportions of women but are underman-
aged based on current clinical risk assessment.39
Clinical Implications and Risk Prediction
Current risk algorithms in common use focus on CHD40 and 
CVD,41 as does the new American College of Cardiology/
American Heart Association Guideline on the Assessment of 
Cardiovascular Risk,42 yet we show that chronic disease, such 
as heart failure and PAD, account for a substantial proportion 
of initial CVD presentations in contemporary practice. These 
diseases are associated with marked increased risk of subse-
quent events and death, yet have been excluded from many 
risk prediction algorithms. Given the recent decline in the 
incidence of acute events of MI and stroke, our findings raise 
the question of whether risk algorithms should take account 
of the current burden of CVDs and, in efforts to personalize 
cardiovascular risk, whether there is a need for risk algo-
rithms tailored to account for specific diseases. For clinical 
use the latter would only have a role if decisions on preven-
tion strategies were altered by using a more specific than a 
more generic risk prediction tool. Our post hoc analysis of the 
discrimination performance of risk prediction models using 
disease-specific age and sex coefficients supports the impor-
tance of having more tailored risk algorithms.
A more nuanced application of age and sex in the clinical 
setting that takes account of their heterogeneous associations 
with different CVDs is provided by the following example: A 
69-year-old woman with untreated hypertension has a 20% 
10-year general risk of CVD, fulfilling guideline criteria for 
primary prevention. With heart failure her most likely ini-
tial CVD presentation within that 10-year time frame (see 
Figure 1), a tailored blood pressure–lowering regime that 
excludes calcium antagonists would optimize CVD preven-
tion because these drugs are relatively less effective at reduc-
ing risk of heart failure.43 At earlier ages, where CHD is the 
more common initial presentation, the choice of blood pres-
sure–lowering medication is likely to make little difference to 
outcomes. This is just 1 example of the way in which under-
standing of the heterogeneity of risks associated with specific 
end points could lead to more personalized risk modification.
We also provide further evidence of the need to protect 
women against CVD with the same vigor as for men. The 
Figure 3. Hazard ratios for men in comparison with women for initial presentation of 12 cardiovascular diseases by baseline age group 
among a population of 1.93 million adults. CHD indicates coronary heart disease; CI, confidence interval; HR, hazard ratio; NOS, not 
otherwise specified; and SCD, sudden cardiac death.
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current strategy of evaluating and treating short-term risk of 
total CVD has the consequence that almost all men aged >70 
should be on treatment, irrespective of their CVD risk factors. 
However, a wider group of people with high risk of specific 
CVDs could be targeted and treated earlier by increasing the 
sensitivity (by extending the time horizon to lifetime, as sug-
gested by the Joint British Societies latest recommendations44) 
and specificity (by using more specific diagnoses) of risk pre-
dictions. Given that the majority of initial CVD presentations 
in our cohort were nonfatal (84% in men and 80% in women), 
such opportunities for earlier intervention via refinement of 
prediction tools should not be missed.
Furthermore, our findings have potentially important con-
sequences for the accuracy of models used to predict CVD 
risk in clinical practice. We found large differences in the 
associations of different CVDs with age (from very weak with 
SAH to very strong with UCD, heart failure, stroke, and AAA) 
and male sex (from negative with SAH to very strong with 
AAA, nonfatal MI, and UCD). So far, most efforts to improve 
the prediction of CVD have focused on refining current mod-
els with new predictors. Although there are several models for 
specific CVDs (eg, heart failure,45 stroke46), current guidelines 
recommend assessment of total CVD risk to simplify clini-
cal decision making.21 Here we show that this one-size-fits-all 
approach reduces the ability to discriminate between individu-
als with high and low risk of specific CVDs.
Implications for Research
Our findings suggest that future research on the primary pre-
vention of CVDs should take account of current patterns of 
disease presentation and redress the imbalance of previous 
literature that has focused extensively on heart attack and 
stroke. Our findings have implications for the design and 
interpretation of observational studies, randomized trials, and 
meta-analyses investigating the primary prevention of CVDs. 
Because the fundamental risk factors of age and sex have such 
heterogeneous associations with different CVDs, and most 
studies are only sufficiently powered to examine CVD aggre-
gates, it is important to account for the relative proportion 
of each disease in the composite end point in meta-analysis. 
Despite an extensive literature on the underlying biological 
and behavioral pathways by which sex may influence aggre-
gates of CVD and CHD, there is a lack of mechanism studies 
that investigate why sex has such heterogeneous associations 
on different CVDs.
Limitations
Our study has important limitations. First, we were not able 
to resolve some disease subtypes, eg, systolic versus dia-
stolic heart failure or ruptured versus nonruptured cases of 
AAA. We did find that the association of MI with male sex 
was more marked for ST-segment–elevation MI than non–ST-
segment–elevation MI, suggesting an even greater degree of 
heterogeneity may be unmasked by investigating more spe-
cific diagnoses. Second, we did not evaluate common CVDs 
that are commonly asymptomatic such as atrial fibrillation. 
Third, EHRs contain limited covariates for explaining the 
heterogeneity in sex differences that we report. Fourth, there 
were 2 less well-specified diagnoses (CHD NOS and stroke 
NOS) which we were unable to resolve further, but which 
we included to ensure all potential initial presentations were 
taken into account. Stroke NOS is likely to be largely isch-
emic stroke, based on proportion of strokes that are ischemic1 
and the behavior of this end point in modeling, indicating that 
we may have overestimated the association of ischemic stroke 
with male sex. We believe CHD NOS is a mixture of stable 
and unstable angina given the associations in this article and 
others, but are unable to substantiate this.
Conclusion
In an era of modern primary prevention, CVDs commonly 
first present with heart failure, transient ischemic attack, stable 
angina, and PAD – diseases that have seldom been the focus of 
primary prevention studies. Predicting CVD risk should take 
account a wide range of CVDs, and the different association 
each has with age and sex, as well.
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CLINICAL PERSPECTIVES
The first lifetime presentation of cardiovascular disease in men and women in the 21st century is not currently well under-
stood, with contemporary studies of sufficient size and clinical resolution to distinguish the most common cardiovascular 
diseases (CVDs) lacking. Traditional cohort studies have, to date, commonly focused on incident heart attack and stroke, but 
it is well recognized that both have been rapidly declining in incidence. Understanding how CVDs first present is important for 
developing primary prevention strategies that protect against specific phenotypes and against the wider cascade of other CVDs 
that often follow. Electronic health records based on usual clinical practice in unselected, contemporary populations provide 
an important opportunity to assess how CVD first presents in women and men across a wide range of 12 different diseases 
affecting the head, heart, abdominal, and peripheral circulations. In a study of 1.9 million adults, 114 859 people experienced 
an incident cardiovascular diagnosis, the majority (66%) of which were neither myocardial infarction nor ischemic stroke. 
Sex has differing associations with different CVDs, with implications for risk prediction and management strategies. Chronic 
disease, such as heart failure and peripheral arterial disease, account for a substantial proportion of initial lifetime CVD pre-
sentations, yet are been excluded from many risk prediction algorithms. Given the recent decline in the incidence of acute 
events, our findings emphasize the relevance of risk algorithms that take account of the current burden of CVDs.
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